Search

Your search keyword '"Cairns, Thomas D"' showing total 34 results
Start Over Author "Cairns, Thomas D"
34 results on '"Cairns, Thomas D"'

8. Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease

Author

Medjeral-Thomas, Nicholas Rhys, primary, Lawrence, Christopher, additional, Condon, Marie, additional, Sood, Bhrigu, additional, Warwicker, Paul, additional, Brown, Heather, additional, Pattison, James, additional, Bhandari, Sunil, additional, Barratt, Jonathan, additional, Turner, Neil, additional, Cook, H. Terence, additional, Levy, Jeremy B., additional, Lightstone, Liz, additional, Pusey, Charles, additional, Galliford, Jack, additional, Cairns, Thomas D., additional, and Griffith, Megan, additional

Published
2020
Full Text
View/download PDF

9. Changing the way HR departments do business through employee self-service

Author

Cairns, Thomas D.

Subjects
Intranets -- Usage, Human resource departments -- Information management, Intranet, Company systems management, Business, Human resources and labor relations
Abstract

The concept of employee self-service emerged as an opportunity for human resource departments to transfer HR transactions to employees through an intranet. This allows HR department to focus less on administrative tasks and more on strategic, value-added processes.

Published
2006

12. The impact of unions on leadership and the corporate three Rs

Author

Cairns, Thomas D.

Subjects
Labor relations -- Evaluation, Labor unions -- Management, Labor unions -- United States, Company business management, Business, Human resources and labor relations
Abstract

A study focuses on the rift caused between a leader and his employee due to interference from labor unions. The importance of the three Rs - right people, right structure and right time - in avoiding interference and promoting effective leadership is emphasized.

Published
2005

13. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis

Author

Wilson, Hannah R., primary, Medjeral-Thomas, Nicholas R., additional, Gilmore, Alyssa C., additional, Trivedi, Pritesh, additional, Seyb, Kathleen, additional, Farzaneh-Far, Ramin, additional, Gunnarsson, Iva, additional, Zickert, Agneta, additional, Cairns, Thomas D., additional, Lightstone, Liz, additional, Cook, H. Terence, additional, and Pickering, Matthew C., additional

Published
2019
Full Text
View/download PDF

14. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis

Author

Pepper, Ruth J, primary, McAdoo, Stephen P, additional, Moran, Sarah M, additional, Kelly, Dearbhla, additional, Scott, Jennifer, additional, Hamour, Sally, additional, Burns, Aine, additional, Griffith, Megan, additional, Galliford, Jack, additional, Levy, Jeremy B, additional, Cairns, Thomas D, additional, Gopaluni, Seerapani, additional, Jones, Rachel B, additional, Jayne, David, additional, Little, Mark A, additional, Pusey, Charles D, additional, and Salama, Alan D, additional

Published
2019
Full Text
View/download PDF

15. Glucocorticoid-free treatment of severe ANCA-associated vasculitis.

Author

Farrah, Tariq E, Prendecki, Maria, Hunter, Robert W, Lahiri, Rashmi, Cairns, Thomas D, Pusey, Charles D, McAdoo, Stephen P, and Dhaun, Neeraj

Subjects
VASCULITIS, HEPATITIS C virus, URINARY tract infections
Abstract

The majority of patients (8/11) had kidney involvement, with 6 patients undergoing kidney biopsy to confirm this (Figure 1A). Two patients underwent an interval kidney biopsy to confirm histologic disease remission (Figure 1B). Eleven patients with active, organ-threatening AAV were treated without any oral or intravenous glucocorticoids (Table 1); six patients presented with de novo disease and five with relapse. Six patients had granulomatosis with polyangiitis (GPA) and five patients had microscopic polyangiitis. [Extracted from the article]

Published
2021
Full Text
View/download PDF

16. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis

Author

Pepper, Ruth J, primary, McAdoo, Stephen P, additional, Moran, Sarah M, additional, Kelly, Dearbhla, additional, Scott, Jennifer, additional, Hamour, Sally, additional, Burns, Aine, additional, Griffith, Megan, additional, Galliford, Jack, additional, Levy, Jeremy B, additional, Cairns, Thomas D, additional, Gopaluni, Seerapani, additional, Jones, Rachel B, additional, Jayne, David, additional, Little, Mark A, additional, Pusey, Charles D, additional, and Salama, Alan D, additional

Published
2018
Full Text
View/download PDF

17. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis

Author

McAdoo, Stephen P, primary, Medjeral-Thomas, Nicholas, primary, Gopaluni, Seerapani, primary, Tanna, Anisha, primary, Mansfield, Nicholas, primary, Galliford, Jack, primary, Griffith, Megan, primary, Levy, Jeremy, primary, Cairns, Thomas D, primary, Jayne, David, primary, Salama, Alan D, primary, and Pusey, Charles D, primary

Published
2018
Full Text
View/download PDF

20. Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients—a potential biomarker of disease activity

Author

Stratigou, Victoria, primary, Doyle, Anne F., additional, Carlucci, Francesco, additional, Stephens, Lauren, additional, Foschi, Valentina, additional, Castelli, Marco, additional, McKenna, Nicola, additional, Cook, H. Terence, additional, Lightstone, Liz, additional, Cairns, Thomas D., additional, Pickering, Matthew C., additional, and Botto, Marina, additional

Published
2017
Full Text
View/download PDF

21. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Author

Goodship, Timothy H.J., primary, Cook, H. Terence, additional, Fakhouri, Fadi, additional, Fervenza, Fernando C., additional, Frémeaux-Bacchi, Véronique, additional, Kavanagh, David, additional, Nester, Carla M., additional, Noris, Marina, additional, Pickering, Matthew C., additional, Rodríguez de Córdoba, Santiago, additional, Roumenina, Lubka T., additional, Sethi, Sanjeev, additional, Smith, Richard J.H., additional, Alpers, Charlie E., additional, Appel, Gerald B., additional, Ardissino, Gianluigi, additional, Ariceta, Gema, additional, Arici, Mustafa, additional, Bagga, Arvind, additional, Bajema, Ingeborg M., additional, Blasco, Miguel, additional, Burke, Linda, additional, Cairns, Thomas D., additional, Carratala, Mireya, additional, D'Agati, Vivette D., additional, Daha, Mohamed R., additional, De Vriese, An S., additional, Dragon-Durey, Marie-Agnès, additional, Fogo, Agnes B., additional, Galbusera, Miriam, additional, Gale, Daniel P., additional, Haller, Hermann, additional, Johnson, Sally, additional, Józsi, Mihály, additional, Karpman, Diana, additional, Lanning, Lynne, additional, Le Quintrec, Moglie, additional, Licht, Christoph, additional, Loirat, Chantal, additional, Monfort, Francisco, additional, Morgan, B. Paul, additional, Noël, Laure-Hélène, additional, O'Shaughnessy, Michelle M., additional, Rabant, Marion, additional, Rondeau, Eric, additional, Ruggenenti, Piero, additional, Sheerin, Neil S., additional, Smith, Jenna, additional, Spoleti, Fabrizio, additional, Thurman, Joshua M., additional, van de Kar, Nicole C.A.J., additional, Vivarelli, Marina, additional, and Zipfel, Peter F., additional

Published
2017
Full Text
View/download PDF

23. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.

Author

McAdoo, Stephen P, Medjeral-Thomas, Nicholas, Gopaluni, Seerapani, Tanna, Anisha, Mansfield, Nicholas, Galliford, Jack, Griffith, Megan, Levy, Jeremy, Cairns, Thomas D, Jayne, David, Salama, Alan D, and Pusey, Charles D

Subjects
CHRONIC kidney failure, WALDENSTROM'S macroglobulinemia, DISEASE remission, RITUXIMAB, GLOMERULAR filtration rate, B cells, THERAPEUTICS
Abstract

Background Current guidelines advise that rituximab or cyclophosphamide should be used for the treatment of organ-threatening disease in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), although few studies have examined the efficacy and safety of these agents in combination. Methods We conducted a single-centre cohort study of 66 patients treated with a combination of oral corticosteroids, rituximab and low-dose pulsed intravenous cyclophosphamide followed by a maintenance regimen of azathioprine and tapered steroid for the treatment of biopsy-proven renal involvement in AAV. Patients were followed for a median of 56 months. Case–control analysis with 198 propensity-matched cases from European Vasculitis Study Group (EUVAS) trials compared long-term differences in relapse-free, renal and patient survival. Results At entry, the median Birmingham Vasculitis Activity Score (BVAS) was 19 and estimated glomerular filtration rate was 25 mL/min. Cumulative doses of rituximab, cyclophosphamide and corticosteroids were 2, 3 and 4.2 g, respectively, at 6 months. A total of 94% of patients achieved disease remission by 6 months (BVAS < 0) and patient and renal survival were 84 and 95%, respectively, at 5 years. A total of 84% achieved ANCA-negative status and 57% remained B cell deplete at 2 years, which was associated with low rates of major relapse (15% at 5 years). The serious infection rate during long-term follow-up was 1.24 per 10 patient-years. Treatment with this regimen was associated with a reduced risk of death {hazard ratio [HR] 0.29 [95% confidence interval (CI) 0.125–0.675], P = 0.004}, progression to end-stage renal disease (ESRD) [HR 0.20 (95% CI 0.06–0.65), P = 0.007] and relapse [HR 0.49 (95% CI 0.25–0.97), P = 0.04] compared with propensity-matched patients enrolled in EUVAS trials. Conclusions This regimen is potentially superior to current standards of care, and controlled studies are warranted to establish the utility of combination drug approaches in the treatment of AAV. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

24. The supply side of labor: HR must be ready to steer organizations to the future

Author

Cairns, Thomas D.

Subjects
United States -- Economic aspects, United States -- Social aspects, United States -- Emigration and immigration, Human resource planning -- Methods, Human resource planning -- Usage, Human resource planning -- Forecasts and trends, Labor market -- Research, Labor market -- Demographic aspects, Baby boom generation -- Appointments, resignations and dismissals, Employers -- Human resource management, Company personnel management, Market trend/market analysis, Business, Human resources and labor relations
Abstract

Human resource (HR) management issues are expected to intensify because of the aging workforce and U.S. population growth due to immigration. Employers must consider the effect of expected retirement of baby boomers and immigration wave on supply and demand for talent and future HR management strategies. How to use the fundamentals of HR planning is also discussed.

Published
2010

25. Talent management at Homeland Security: a corporate model suggests a recipe for success

Author

Cairns, Thomas D.

Subjects
United States. Department of Homeland Security -- Human resource management, General Electric Co. -- Human resource management, Electrical equipment and supplies industry -- Human resource management, Company personnel management, Business, Human resources and labor relations
Abstract

The talent-management process at General Electric is compared with that of the Department of Homeland Security. GE's Session-C process with some changes may be used for talent management at the agency. The Session-C process aims to evaluate the organization's leadership talent.

Published
2009

33. novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis.

Author

Pepper, Ruth J, McAdoo, Stephen P, Moran, Sarah M, Kelly, Dearbhla, Scott, Jennifer, Hamour, Sally, Burns, Aine, Griffith, Megan, Galliford, Jack, Levy, Jeremy B, Cairns, Thomas D, Gopaluni, Seerapani, Jones, Rachel B, Jayne, David, Little, Mark A, Pusey, Charles D, and Salama, Alan D

Subjects
THERAPEUTIC use of glucocorticoids, VASCULITIS
Abstract

A correction to the article "A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis" is presented.

Published
2019
Full Text
View/download PDF

34. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis

Author

McAdoo, Stephen P, Medjeral-Thomas, Nicholas, Gopaluni, Seerapani, Tanna, Anisha, Mansfield, Nicholas, Galliford, Jack, Griffith, Megan, Levy, Jeremy, Cairns, Thomas D, Jayne, David, Salama, Alan D, and Pusey, Charles D

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Remission Induction, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Middle Aged, Prognosis, 3. Good health, Cohort Studies, Survival Rate, Young Adult, Case-Control Studies, Antineoplastic Combined Chemotherapy Protocols, Azathioprine, Disease Progression, Humans, Kidney Failure, Chronic, Female, Kidney Diseases, Rituximab, Cyclophosphamide, Aged, Follow-Up Studies, Glomerular Filtration Rate
Abstract

Background. Current guidelines advise that rituximab or cyclophosphamide should be used for the treatment of organthreatening disease in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), although few studies have examined the efficacy and safety of these agents in combination. Methods. We conducted a single-centre cohort study of 66 patients treated with a combination of oral corticosteroids, rituximab and low-dose pulsed intravenous cyclophosphamide followed by a maintenance regimen of azathioprine and tapered steroid for the treatment of biopsy-proven renal involvement in AAV. Patients were followed for a median of 56 months. Case– control analysis with 198 propensity-matched cases from European Vasculitis Study Group (EUVAS) trials compared long-term differences in relapse-free, renal and patient survival. Results. At entry, the median Birmingham Vasculitis Activity Score (BVAS) was 19 and estimated glomerular filtration rate was 25 mL/min. Cumulative doses of rituximab, cyclophosphamide and corticosteroids were 2, 3 and 4.2 g, respectively, at 6 months. A total of 94% of patients achieved disease remission by 6 months (BVAS < 0) and patient and renal survival were 84 and 95%, respectively, at 5 years. A total of 84% achieved ANCA-negative status and 57% remained B cell deplete at 2 years, which was associated with low rates of major relapse (15% at 5 years). The serious infection rate during long-term follow-up was 1.24 per 10 patient-years. Treatment with this regimen was associated with a reduced risk of death {hazard ratio [HR] 0.29 [95% confidence interval (CI) 0.125–0.675], P ¼ 0.004}, progression to end-stage renal disease (ESRD) [HR 0.20 (95% CI 0.06–0.65), P ¼ 0.007] and relapse [HR 0.49 (95% CI 0.25–0.97), P ¼ 0.04] compared with propensity-matched patients enrolled in EUVAS trials. Conclusions. This regimen is potentially superior to current standards of care, and controlled studies are warranted to establish the ut

Catalog

Books, media, physical & digital resources
See catalog results